Publications by authors named "Yevgeniy Samyshkin"

Claim this Profile
C
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.
Shinsuke Iida, Yusuke Yasutomi, Yevgeniy Samyshkin, Yi-Chen Chen, Chi-Chang Chen

PLoS One· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure.
Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, Eric M Maiese, Leah Sansbury

Value Health· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Domenica Lorusso, Holly Guy, Yevgeniy Samyshkin, Carol Hawkes, Kasey Estenson

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Andreas Nikolaou, Apoorva Ambavane, Anshul Shah, Wenkang Ma, Jon Tosh, Yevgeniy Samyshkin

Expert Rev Hematol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Anshul Shah, Jonathan C Tosh, Apoorva Ambavane, Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin

Clinicoecon Outcomes Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension.
David G Kiely, Orla Doyle, Edmund Drage, Harvey Jenner, Valentina Salvatelli, Yevgeniy Samyshkin

Pulm Circ· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project.
Rito Bergemann, James Allsopp, Harvey Jenner, Flora Ashley Daniels, Edmund Drage, Yevgeniy Samyshkin

Pulm Circ· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, Andrew H Briggs, Sixten Borg, Yevgeniy Samyshkin

Value Health· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.
Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, Andrew H Briggs, Ryan N Hansen, Yevgeniy Samyshkin

Value Health· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.
Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, Sixten Borg, Ryan N Hansen, Yevgeniy Samyshkin

Value Health· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Yevgeniy Samyshkin, Robert W Kotchie, Ann-Christin Mörk, Andrew H Briggs, Eric D Bateman

Eur J Health Econ· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Yevgeniy Samyshkin, Michael Schlunegger, Susan Haefliger, Sabine Ledderhose, Matthew Radford

Int J Chron Obstruct Pulmon Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
Yevgeniy Samyshkin, Anne-Laure Guillermin, Jennie H Best, Steven C Brunell, Adam Lloyd

J Med Econ· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Won Chan Lee, Yevgeniy Samyshkin, Jakob Langer, James L Palmer

J Med Econ· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Anne-Laure Guillermin, Adam Lloyd, Jennie H Best, Mary Beth DeYoung, Yevgeniy Samyshkin

J Med Econ· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Nadine Hertel, Robert W Kotchie, Yevgeniy Samyshkin, Matthew Radford, Samantha Humphreys

Int J Chron Obstruct Pulmon Dis· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Anne-Laure Guillermin, Yevgeniy Samyshkin, Donna Wright, Tini Nguyen, Julie Villeneuve

J Med Econ· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mental health care reforms in Europe: Rehabilitation and social inclusion of people with mental illness in Russia.
Rachel Jenkins, David McDaid, Alexey Nikiforov, Angelina Potasheva, Jonathan Watkins, Yevgeniy Samyshkin

Psychiatr Serv· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of stroke unit care followed by early supported discharge.
Omer Saka, Victoria Serra, Yevgeniy Samyshkin, Alistair McGuire, Charles C D A Wolfe

Stroke· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mental health reform in the Russian Federation: an integrated approach to achieve social inclusion and recovery.
Rachel Jenkins, Stuart Lancashire, David McDaid, Yevgeniy Samyshkin, Samantha Green

Bull World Health Organ· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-systems efficiency in the Russian Federation: tuberculosis control.
Katherine Floyd, Raymond Hutubessy, Yevgeniy Samyshkin, Alexei Korobitsyn, Ivan Fedorin

Bull World Health Organ· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis